AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01170806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
Study NCT02245789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
Study NCT02245789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Description: Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
Study NCT02245789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and remifentanil anesthesia
Description: The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
Study NCT02245789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil anesthesia
Description: The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
Study NCT04352751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: convalescent plasma
Description: * Plasmapheresis, 900 - 1000 mL each time.~* Standard apheresis plasma collection protocol using Haemonetics MCS+ intermittent blood flow system or Terumo Optia, Cobe-Spectra, Trima or Fresenius continuous flow system to be used.~* Isovolumic saline replacement should be done.~* Each donor can donate convalescent plasma again after an interval of every 2 weeks
Study NCT03659305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-001
Description: Concentrate for preparation solution for infusion in ampules, 25 mg/mL
Study NCT03659305 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Concentrate for preparation solution for infusion in ampules, 25 mg/mL
Study NCT01028157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS: Sistas Talking About Real Solutions
Description: The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
Study NCT01028157 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health & Nutrition
Description: Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
Study NCT02679859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNP guided medical therapy optimisation
Study NCT01113632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
Study NCT03471533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutraceutical: experimental product
Description: 84 days of consumption
Study NCT03471533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 84 days of consumption
Study NCT04291339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen technique
Description: High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
Study NCT04291339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mask ventilation technique
Description: Oxygen will be supplied through the mouth and nose to the patients using facial mask during anesthetic induction. Pulse oximetry and oxygen reserve index will be monitored continuously.
Study NCT02578927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GT+Ex
Description: In this session the volunteers ingested capsules with 2g of powder green tea before exercise
Study NCT02578927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PL+Ex
Description: In this session the volunteers ingested capsules with 2g of placebo before exercise
Study NCT02578927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
Study NCT03040635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single oral doses of Risdiplam will be administered on Day 1.
Study NCT03040635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral doses of Risdiplam matching placebo will be administered on Day 1.
Study NCT03330938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBI and Resilience
Description: A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
Study NCT03330938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral Intervention
Description: Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
Study NCT00922883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study NCT01051128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prometra Programmable Implantable Pump System
Description: The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
Study NCT02948491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Song that the mother sings to the child before birth, recording of the mother's voice.
Study NCT02114879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation
Description: Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
Study NCT02114879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation
Description: Daily PT/OT provided by therapists not trained in the treatment intervention.
Study NCT02098109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XM02 Filgrastim
Study NCT02098109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Study NCT02098109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis
Study NCT02098109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Study NCT02098109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor
Study NCT02098109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study NCT02098109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant
Study NCT02098109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Study NCT00496847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERIOGEN
Description: Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
Study NCT00496847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta TCP alone
Description: Implantation of β-TCP (0.5 g) alone
Study NCT01116232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
Study NCT01116232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes.
Study NCT01116232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
Study NCT01116232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
Study NCT01116232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: laboratory biomarker analysis
Study NCT01116232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: allogeneic hematopoietic stem cell transplantation
Study NCT01116232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: management of therapy complications
Study NCT01116232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: peripheral blood stem cell transplantation
Study NCT00500292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily oral tablet two dose strengths
Study NCT00500292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Description: intravenous infusion
Study NCT00500292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Description: intravenous infusion
Study NCT01894789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Blinded administration of ticagrelor for 10 days
Study NCT01894789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Blinded administration of ticagrelor for 10 days
Study NCT01894789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Blinded administration of clopidogrel and placebo for 10 days
Study NCT01894789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Blinded administration of clopidogrel and placebo for 10 days
Study NCT03168152 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Microwave Ablation (MWA)
Description: MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
Study NCT03168152 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
Study NCT01894152 — intervention group
Intervention type: DEVICE
Intervention: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Description: Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Study NCT02741700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gout Storytelling Video Intervention
Description: The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
Study NCT02741700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gout Storytelling Video Intervention
Description: The investigators developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management, which were narrated by several Veterans with gout. One of the veterans also presented a PowerPoint on gout and its management. The intervention was shown to the participants on a touchscreen computer or the desktop screen at the baseline study visit. Subsequently, they were provided with DVD with similar intervention to watch at home.
Study NCT02251951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
Study NCT02372851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pureit As+ Filter
Description: The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
Study NCT03144882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin Pill
Description: Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
Study NCT03144882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03234660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
Study NCT03234660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 0.9% normal saline continuous infusion
Study NCT05091008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet
Description: proper history was taken. HCV genotyping was done revealed GT 4 in all included patients. Basic ECG and abdominal US were performed prior to treatment. Concomitant HBV infection was excluded by HBs Ag and anti-HBc antibody HIV screening was done prior to treatment. Basic investigations were done prior to therapy. All included patients received Ledipasvir-Sofosbuvir fixed-dose combination one tablet (90 mg Ledipasvir, 400 mg Sofosbuvir), orally once daily at a fixed time with or without food for 12 weeks. Regular visits were arranged at 4, 8, and 12 weeks with easy access to the pediatric hepatology unit and the treating physician if any urgent problem in between the visits. Every visit, laboratory investigations were checked. Adverse events (after excluding other possible causes) were reported for the safety profile of the drug. The efficacy of the drug, HCV-RNA was assessed by quantitative real-time PCR at 4 weeks and after the end of the treatment course (12 weeks)
Study NCT02641379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\\n
Study NCT02641379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is available as 200 mg tablets
Study NCT00623649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCH 916
Description: Dose escalation study with a full review of all safety data following each cohort.
Study NCT00623649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose escalation study with a full review of all safety data following each cohort.
Study NCT02017314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02723149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marijuana Approach Avoidance Training
Description: Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
Study NCT02723149 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Marijuana Approach Avoidance Training
Description: Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
Study NCT00721786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCSF/SFGH Internet Stop Smoking Study site
Description: Internet stop smoking site in Spanish and English
Study NCT00256152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AF Suppression Pacing Algorithm
Study NCT01478126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N(2)-L-Alanine L-Glutamine dipeptide
Description: Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
Study NCT01478126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
Study NCT04552587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart APP
Description: The HEART intervention includes a care planning visit for patients and caregivers and an App for caregivers focused on nutrition, self-care and support.
Study NCT01083212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Single dose,oral tablet
Study NCT01083212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Oral tablet bid on day 1 - 5.
Study NCT01083212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet bid on day 1-5
Study NCT00506155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10 mg/kg by vein over 90 minutes
Study NCT00506155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m\^2 by vein over 4 hours
Study NCT00506155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 30 mg/m\^2 by vein over 15 minutes